Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.83 |
| ▸ | RAF1 | P04049 | 2/20 | 0.83 |
| ▸ | LYN | P07948 | 2/20 | 0.83 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.83 |
| ▸ | EGFR | P00533 | 1/20 | 0.83 |
| ▸ | BRAF | P15056 | 1/20 | 0.83 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.83 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.83 |
| ▸ | AKT1 | P31749 | 1/20 | 0.83 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.69 |
| ▸ | SRC | P12931 | 10/20 | 0.55 |
| ▸ | GSK3A | P49840 | 9/20 | 0.48 |
| ▸ | SYK | P43405 | 8/20 | 0.47 |
| ▸ | SCARB1 | Q8WTV0 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4456684 | 0.93 | ABL1 (0.88) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL4092237 | 0.91 | ABL1 (1.00) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6613542 | 0.91 | ABL1 (0.83) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL4092566 | 0.90 | ABL1 (0.81) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6609355 | 0.90 | ABL1 (0.81) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL4082365 | 0.89 | ABL1 (0.86) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL4081446 | 0.88 | ABL1 (0.82) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6610422 | 0.88 | ABL1 (0.81) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL4091655 | 0.88 | ABL1 (0.84) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6609488 | 0.88 | ABL1 (0.84) | ABL1RAF1LYNMAPK9EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116245-A2 | EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| US-20050163726-A1 | Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-28 | — | — | US | disclosed |
| US-6358945-B1 | CYTOKINE, TUMOR NECROSIS FACTOR, AND INTERLEUKIN INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050163726-A1 | Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors | CHRM3, CHRNB1, CHRM2 | ABL1 1495/4885RAF1 931/4885LYN 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.